[{"id":"d706a100-20c3-4942-98f1-dac486c56909","acronym":"ORIENTA","url":"https://clinicaltrials.gov/study/NCT06102824","created_at":"2023-10-26T15:14:20.313Z","updated_at":"2024-07-02T16:35:23.595Z","phase":"Phase 2","brief_title":"Organoid-based Functional Precision Therapy for Advanced Breast Cancer","source_id_and_acronym":"NCT06102824 - ORIENTA","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HR positive • HER-2 negative • ER positive + PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • ER positive + PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • albumin-bound paclitaxel • cyclophosphamide • Halaven (eribulin mesylate) • pegylated liposomal doxorubicin • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy) • Ixempra (ixabepilone) • Lipusu (liposomal paclitaxel) • utidelone IV (UTD1)"],"overall_status":"Recruiting","enrollment":" Enrollment 252","initiation":"Initiation: 01/20/2024","start_date":" 01/20/2024","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-01-12"},{"id":"cf6dacb7-4d9a-469d-8ec3-f848632eebdf","acronym":"UTILIZABLE","url":"https://clinicaltrials.gov/study/NCT06125080","created_at":"2023-11-09T16:12:55.735Z","updated_at":"2024-07-02T16:35:29.674Z","phase":"Phase 2","brief_title":"The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study","source_id_and_acronym":"NCT06125080 - UTILIZABLE","lead_sponsor":"Huihua Xiong","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 expression • ER expression","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • ER expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tevimbra (tislelizumab-jsgr) • utidelone IV (UTD1)"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 10/30/2023","start_date":" 10/30/2023","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2023-11-09"},{"id":"2e392cea-8b8d-4662-ad20-4a08684c1944","acronym":"","url":"https://clinicaltrials.gov/study/NCT05673629","created_at":"2023-01-06T15:58:41.540Z","updated_at":"2024-07-02T16:35:29.915Z","phase":"Phase 3","brief_title":"Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer","source_id_and_acronym":"NCT05673629","lead_sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • doxorubicin hydrochloride • cyclophosphamide • utidelone IV (UTD1)"],"overall_status":"Recruiting","enrollment":" Enrollment 552","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-08"},{"id":"dc4703be-c83b-4bad-8dcf-01bbc84cc5ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT05673590","created_at":"2023-01-06T15:58:41.007Z","updated_at":"2024-07-02T16:35:29.952Z","phase":"Phase 3","brief_title":"Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05673590","lead_sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • EGFR T790M • ALK fusion • EGFR positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • EGFR T790M • ALK fusion • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • utidelone IV (UTD1)"],"overall_status":"Recruiting","enrollment":" Enrollment 612","initiation":"Initiation: 05/12/2023","start_date":" 05/12/2023","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-08"},{"id":"5eec34c9-7beb-49a4-a2c7-9012b054777f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681287","created_at":"2021-01-19T20:46:42.670Z","updated_at":"2024-07-02T16:35:35.921Z","phase":"Phase 2","brief_title":"Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.","source_id_and_acronym":"NCT04681287","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • capecitabine • albumin-bound paclitaxel • vinorelbine tartrate • Cipterbin (inetetamab) • utidelone IV (UTD1)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 04/23/2021","start_date":" 04/23/2021","primary_txt":" Primary completion: 11/04/2021","primary_completion_date":" 11/04/2021","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-09-25"},{"id":"9f5f5828-6d10-4094-880b-322fc5ecbb08","acronym":"","url":"https://clinicaltrials.gov/study/NCT05983094","created_at":"2023-08-09T14:09:24.106Z","updated_at":"2025-02-25T12:29:42.410Z","phase":"Phase 2","brief_title":"Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer","source_id_and_acronym":"NCT05983094","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + HR negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • HER-2 negative + HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • epirubicin • utidelone IV (UTD1)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 181","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2023-08-09"},{"id":"ceb56eef-c6c4-4914-b90d-4d55eb9d4b1d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05430399","created_at":"2022-06-24T15:56:29.284Z","updated_at":"2024-07-02T16:35:43.046Z","phase":"Phase 3","brief_title":"Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05430399","lead_sponsor":"Sun Yat-sen University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • utidelone IV (UTD1)"],"overall_status":"Recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 06/21/2022","start_date":" 06/21/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2023-07-13"},{"id":"fe84c8e7-fd76-4304-8ebb-e264209650a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05403333","created_at":"2022-06-03T12:55:13.625Z","updated_at":"2024-07-02T16:36:09.395Z","phase":"Phase 2","brief_title":"Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05403333","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e utidelone IV (UTD1)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 06/10/2022","start_date":" 06/10/2022","primary_txt":" Primary completion: 03/09/2023","primary_completion_date":" 03/09/2023","study_txt":" Completion: 03/09/2025","study_completion_date":" 03/09/2025","last_update_posted":"2022-06-03"},{"id":"dc1b1acf-7135-45a1-8a39-9849bf627339","acronym":"","url":"https://clinicaltrials.gov/study/NCT05398861","created_at":"2022-06-01T16:00:18.876Z","updated_at":"2024-07-02T16:36:09.637Z","phase":"Phase 2","brief_title":"Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer","source_id_and_acronym":"NCT05398861","lead_sponsor":"Henan Cancer Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Ankeda (bevacizumab biosimilar) • utidelone IV (UTD1)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2022-06-01"},{"id":"e6acf6b8-3e49-47a8-a08e-d0435abcd654","acronym":"","url":"https://clinicaltrials.gov/study/NCT05172518","created_at":"2021-12-29T13:53:37.875Z","updated_at":"2024-07-02T16:36:19.071Z","phase":"Phase 3","brief_title":"Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05172518","lead_sponsor":"Sun Yat-sen University","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • capecitabine • albumin-bound paclitaxel • utidelone IV (UTD1)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 512","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2030","study_completion_date":" 03/01/2030","last_update_posted":"2021-12-29"}]